These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 16469301)

  • 1. Target-mediated drug disposition and dynamics.
    Mager DE
    Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
    Gibiansky L; Gibiansky E
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of target-mediated drug disposition.
    Peletier LA; Gabrielsson J
    Eur J Pharm Sci; 2009 Dec; 38(5):445-64. PubMed ID: 19786099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.
    An G
    J Clin Pharmacol; 2020 Feb; 60(2):149-163. PubMed ID: 31793004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview.
    An G
    J Clin Pharmacol; 2017 Feb; 57(2):137-150. PubMed ID: 27489162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study.
    Bach T; Jiang Y; Zhang X; An G
    J Clin Pharmacol; 2019 Mar; 59(3):394-405. PubMed ID: 30387863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
    Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
    J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative structure-pharmacokinetic/pharmacodynamic relationships.
    Mager DE
    Adv Drug Deliv Rev; 2006 Nov; 58(12-13):1326-56. PubMed ID: 17092600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors.
    Yamazaki S; Shen Z; Jiang Y; Smith BJ; Vicini P
    Drug Metab Dispos; 2013 Jun; 41(6):1285-94. PubMed ID: 23557746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
    Luu KT; Bergqvist S; Chen E; Hu-Lowe D; Kraynov E
    J Pharmacol Exp Ther; 2012 Jun; 341(3):702-8. PubMed ID: 22414855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.
    Marathe A; Krzyzanski W; Mager DE
    J Pharmacokinet Pharmacodyn; 2009 Jun; 36(3):199-219. PubMed ID: 19434483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
    Beaumont K; Smith DA
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-target residence time and its implications for lead optimization.
    Copeland RA; Pompliano DL; Meek TD
    Nat Rev Drug Discov; 2006 Sep; 5(9):730-9. PubMed ID: 16888652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.